Literature DB >> 31894937

Lymphoma: Diagnosis and Treatment.

William D Lewis1, Seth Lilly1, Kristin L Jones1.   

Abstract

Lymphoma is a group of malignant neoplasms of lymphocytes with more than 90 subtypes. It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma. Approximately 82,000 new U.S. patients are diagnosed with lymphoma annually. Any tobacco use and obesity are major modifiable risk factors, with genetic, infectious, and inflammatory etiologies also contributing. Lymphoma typically presents as painless adenopathy, with systemic symptoms of fever, unexplained weight loss, and night sweats occurring in more advanced stages of the disease. An open lymph node biopsy is preferred for diagnosis. The Lugano classification system incorporates symptoms and the extent of the disease as shown on positron emission tomography/computed tomography to stage lymphoma, which is then used to determine treatment. Chemotherapy treatment plans differ between the main subtypes of lymphoma. Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP), bendamustine, and lenalidomide. Hodgkin lymphoma is treated with combined chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), Stanford V (a chemotherapy regimen consisting of mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone), or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) with radiotherapy. Subsequent chemotherapy toxicities include neuropathy, cardiotoxicity, and secondary cancers such as lung and breast, and should be considered in the shared decision-making process to select a treatment regimen. Once remission is achieved, patients need routine surveillance to monitor for complications and relapse, in addition to age-appropriate screenings recommended by the U.S. Preventive Services Task Force. Patients should receive a 13-valent pneumococcal conjugate vaccine followed by a 23-valent pneumococcal polysaccharide vaccine at least eight weeks later with additional age-appropriate vaccinations because lymphoma is an immunosuppressive condition. Household contacts should also be current with their immunizations.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31894937

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  6 in total

1.  Follicular lymphoma without lymphadenopathy incidentally diagnosed by sentinel lymph node biopsy during breast cancer surgery: a case report.

Authors:  Emiko Hiraoka; Norio Masumoto; Takaoki Furukawa; Norimasa Kuraoka; Ichiro Nagamine; Aya Kido; Kazuhiro Sentani; Sunao Ootagaki
Journal:  Surg Case Rep       Date:  2022-09-13

2.  Lymphoma cell-derived extracellular vesicles inhibit autophagy and apoptosis to promote lymphoma cell growth via the microRNA-106a/Beclin1 axis.

Authors:  Junling Tang; Peng Hu; Shixia Zhou; Tiejun Zhou; Xiaoming Li; Li Zhang
Journal:  Cell Cycle       Date:  2022-03-13       Impact factor: 5.173

3.  The diagnostic performance of whole-body MRI in the staging of lymphomas in adult patients compared to PET/CT and enhanced reference standard-systematic review and meta-analysis.

Authors:  Lukas Lambert; Andrea Burgetova; Marek Trneny; Bianka Bircakova; Jan Molinsky; Katerina Benesova; David Zogala; Pavel Michalek
Journal:  Quant Imaging Med Surg       Date:  2022-02

4.  Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.

Authors:  Alexandra-Cristina Paunescu; Christiane Bergman Copie; Sandra Malak; Steven Le Gouill; Vincent Ribrag; Krimo Bouabdallah; David Sibon; Gerhard Rumpold; Marie Preau; Nicolas Mounier; Corinne Haioun; Fabrice Jardin; Caroline Besson
Journal:  Ann Hematol       Date:  2021-10-06       Impact factor: 3.673

5.  Correlation of SARS‑CoV‑2 to cancer: Carcinogenic or anticancer? (Review).

Authors:  Ying-Shuang Li; Hua-Cheng Ren; Jian-Hua Cao
Journal:  Int J Oncol       Date:  2022-03-02       Impact factor: 5.650

6.  Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study.

Authors:  Tianwang Guan; Zicong Qiu; Miao Su; Jinming Yang; Yongshi Tang; Yanting Jiang; Dunchen Yao; Yanxian Lai; Yanfang Li; Cheng Liu
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.